



SUBJECT INDEX

- Abecarnil, 87, 1005
Aberrant drinking, 33
Absence, 73
Acetylcholine, 179, 679, 783, 809
ACTH, 517, 641, 965
ACTH analog, 163
Activity, 303, 701
Addiction, 11, 433, 791, 809
Adenosine A₁ receptors, 341
Adjunctive behavior, 123
Adrenal weight, 965
Aging, 641
Agonists, 995
Agouti, 425
Aggression, 329
Aggressive behavior, 951
Alcohol, 585
Alcohol aversion, 487
Alcohol intake, 891
Alcohol-nonpreferring rats, 487, 585
Alcohol-preferring rats, 487, 585
Alcohol reinforcement, 487
Alcohol sensitivity, 585, 723
Alcohol tolerance, 585
 α -Methyl-*p*-tyrosine, 379
 α MPT, 1
 α_1 -Adrenoceptors, 1017
 α_2 -Adrenoceptors, 291, 1017
Alphaxalone, 777
Allo pregnanolone, 777
Amino acids, 549
Amnesia, 391
Amphetamine, 511, 695, 741, 817, 833
Anabolic-androgenic steroids, 329
Analgesia, 133, 567, 665, 927, 943
Androgen, 741
Androgen-dependent behavior, 213
Animal model, 11, 123
Aniracetam, 277, 943
Anorexant khat, 297
Anorexia, 839
Anorexia nervosa, 123, 433
Antagonists, 995
Antianxiety, 493
Anticonvulsant, 87
Anticonvulsant drugs, 559
Antinociception, 205, 411, 449, 567, 943
Antipsychotic, 493
Anxiety, 271, 369, 541, 825, 1005
Anxiogenic drugs, 271
Anxiolysis, 87
Anxiolytics, 271, 369, 753, 825
A₁ receptors, 249
Apomorphine, 335, 417, 817, 833
Aprophen, 463
Arecoline, 713
Associative learning, 649
Atropine, 463
Attention, 163, 213, 617
Atypical opioid systems, 433
Audiogenic-like seizures, 503
Audiogenic seizures, 503
Auto-addiction, 433
Aversion, 511
(*A^{VY}*), 425
Baclofen, 73, 303
Barakol, 753
Behavior, 493, 995
Behavior genetics, 623
Benactyzine, 463
Benzodiazepine, 1, 87, 593, 1005
Benzodiazepine receptors, 581, 723
Benzoylconidine, 133
 β -Adrenoceptor antagonists, 903
 β -Adrenoceptors, 1017
 β -Endorphin, 425
 β -FNA, 927
Bicuculline, 629, 673
Black bear, 885
Blink reflex, 857
Body temperature, 657
Body weight, 657
Brain, 205, 843
Brain angiotensin, 687
Brain cholinergic systems, 687
Brain damage, 163
Brain injury, 679
Brain monoamines, 469
Brain phospholipid, 843
Brain serotonergic systems, 687
Branched-chain amino acids, 449
Bretazenil, 723
Bromocriptine, 833
Burimamide, 567
Cadmium, 687
Cadmium intoxication, 687
Cadmium neurotoxicity, 687
Calcium-calmodulin protein kinase activity, 155
Calorimetry, 549
Cannabinoid, 657
Cannabis, 657
Carbamazepine, 243, 559
Carbon monoxide, 355
Cardiovascular, 927
Cardiovascular responses, 927
Cassia siamea, 753
Catalepsy, 437
Catecholamines, 141, 213
CCK, 493
CCPA, 249
Central administration, 665
Cerebellum, 147
CGP 35348, 943
CGS8216, 87
Chicken embryo, 603
Chlordiazepoxide, 593
Chlorpromazine, 115
Choline, 783
Cholinergic activity, 613
Cholinergic antagonist, 463
Cholinergic neurochemistry, 771
Cholinergic pathways, 735
Cholinergic stimulation, 1017
Cholinergic system, 713
Cholinesterase inhibition, 771
Chronic administration, 935
Chronic ethanol, 249
Chronic methamphetamine, 437
Chronic stress, 517
Cigarettes, 355
Cingulate cortex, 617
Circadian, 843
Circadian rhythm, 141
Circadian wheel-running activity, 843
Citalopram, 825
Classical conditioning, 147
Clonidine, 1, 291, 979
CO₂, 205
Cocaethylene, 133
Cocaine, 5, 57, 185, 191, 133, 227, 243,
525, 623, 695, 747, 863, 911, 919
Conditioned fear stress, 825
Conditioned place preference, 99, 185, 191,
531, 657
Conditioned taste aversion, 243, 657, 891
Conditioned taste avoidance, 657
Conflict behavior, 369
Conflict responding, 593
Continuous drug infusion, 713
Convulsions, 493
Corticosterone, 641
CP 55,940, 657
CPP, 799
Crab, 441
Crack, 57
Cromakalim, 839
Cue learning, 303
Cyproheptadine, 441
d-Amphetamine, 297
DA D₂ receptors, 525
DAMGO, 927
Daytime activity, 265
Defensive reflex, 857
Dehydroepiandrosterone, 51

- d*-Fenfluramine, 641
δ-Opioid receptor, 477
δ-Receptor, 665
 Dependence, 11, 791
 Depression, 535
 Development, 41, 425, 603
 Dexfenfluramine, 549
D-Fenfluramine, 155
 Diazepam, 115, 271, 317, 753, 1005
 Diestrus-2, 965
 Dizocilpine, 701
D-Norfenfluramine, 155
 DOI, 603
 Dominance, 285
 Dominance rank, 11
*D*₁ receptors, 481, 759
 DOPAC, 41, 575
 Dopamine, 41, 99, 179, 221, 257, 285, 417, 455, 493, 575, 641, 695, 863
 Dopamine agonists, 481, 759
 Dopamine antagonists, 481, 759
 Dopamine (DA), 425
 Dopamine *D*₁ receptors, 935
 Dopamine *D*₂/*D*₃ receptors, 935
 Dopamine neurotransmission, 107
 Dopamine receptor supersensitivity, 185
 Dopamine release, 155
 Dopaminergic stimulation, 1017
 Dothiepin, 265
 DPDPE, 885
 [*D*-Pen⁵]-enkephalin, 877
 [*D*-Pen³]-enkephalin, 877
 Drinking, 347
 Drinking behavior, 687
 Drug abuse, 657, 871
 Drug aerosols, 57
 Drug discrimination, 107, 455, 891, 979
 Drug reinforcement, 477
 Drug reward, 511
 Drugs of abuse, 243, 617
 DSP-4, 213, 391
D, Receptor, 695
*D*₁ dopamine receptors, 291
*D*₂ Receptor, 695, 759
 Duration, 965
 Dynorphin A, 885
 Eating disorders, 433
 Egonine, 133
 Egonine methyl ester, 133
 EEG, 73
 8-OH-DPAT, 323, 385
 Ejaculation, 329
 Electrophysiology, 493
 Elevated plus-maze, 271, 753
 Elicited PGO waves, 323
 Endogenous opioid peptides, 81
 Endogenous opioids, 613
 Energy metabolism, 549
 Environment-specific sensitization, 899
 Epilepsy, 73
 Essential, 843
 Essential fatty acids, 843
 Estrogen, 27
 Ethanol, 11, 51, 891, 919, 971
 Ethanol alcohol preference, 33
 Ether stress, 965
 Eticlopride, 759
 Etonitazene, 11, 871
 Evoked potentials, 817
 Exploratory head dipping, 877
 Ex vivo binding, 41
 Fear, 649
 Feeding, 1005
 Felbamate, 559
 Female, 433
 Female F-344 rat, 641
 Fenfluramine, 99, 511
 FG5865 Fimbria lesion, 163
5β-Pregnanediol, 777
5-HIAA, 965
5-HT (5-hydroxytryptamine, serotonin), 995
5-HT receptors, 107
*5-HT*_{1A} receptor, 385, 825
*5-HT*_{1B} receptors, 257
*5-HT*_{1D}, 535
*5-HT*₂ receptors, 271, 765
*5-HT*_{2C} receptor, 107, 385
 5-Hydroxytryptamine, 33, 1023
5,7-DHT, 951
 Fixed-ratio schedule, 979
 Flunarizine, 155
 Fluvoxamine, 265
 Food, 995
 Food competition, 951
 Food intake, 221, 297, 425, 433, 777, 839, 1023
 Food-related drinking, 347
 Food restriction, 995
 Food reward, 221
 Foot-shock, 735
 Forced, 843
 Forced swimming, 469
 Forced swimming test, 843
 Formalin, 411
 Fowls, 995
 Free fatty acids, 549
 Freezing behavior, 825
 Functional recovery, 163
 GABA, 27, 51, 629, 943, 995
 GABA (γ -aminobutyric acid), 995
GABA_A, 971
GABA_A receptors, 361
GABA_A receptor subtypes, 723
GABA_B, 73, 303
GABA_B receptor, 943
GABA_A receptor, 777
γ-Butyrolactone, 73
γ-Hydroxybutyric acid, 73
γ-Linolenic, 843
γ-Linolenic acid, 843
 Gastric emptying, 839
 Gastric lesion, 957
 GBR12909, 911
 Generalization, 891
 Genetics, 425, 585, 871
 Ginger, 271
Ginkgo biloba, 271
 Glucose, 549
 Glycine, 791
 Glycogen, 549
 Gnawing behavior, 67
 GR 127935, 535
 Grooming, 935
 Guinea pig, 799
 Guinea pig ileum, 885
 Habituation, 401, 517, 857
 HAD rats, 33
 Halcion, 317
 Haloperidol, 401, 437, 833, 853
 Handling for vaginal smear screening, 965
 Hibernation, 885
 Hibernation-induction trigger, 885
 High responder, 191
 Hippocampus, 361, 613, 899
 Histamine, 347
*Histamine H*₁-receptor antagonist, 567
*Histamine H*₃-receptor antagonist, 567
*Histamine H*₂-receptor agonist, 567
*Histamine H*₂-receptor antagonist, 567
 Histaminergic, 347
*H*₁ receptors, 347
 Horizontal activity, 877
 Hormone, 27
 Hot-plate analgesia test, 449
 HPNS, 257
*H*₃ receptors, 347
*H*₂ receptors, 347
 Hyperactivity, 185
 Hyperphagia, 87, 1005
 Hypoalgesia, 649
 Hypothalamic 5-HT, 965
 Hypothalamus, 425
 Hypothermia, 87, 657
 Ibogaine, 863
 Immunity, 227
 Impromidine, 567
 Individual differences, 191, 511
 Indole levels and release, 155
 Inferior colliculus lesions, 503
 Inferior colliculus nuclei, 503
 Infusion, 309
 Ingestion, 731
 Ingestive behavior, 657
 Insulin, 549
 Intracerebral injection, 541
 Intracranial self-stimulation, 741
 Intrauterine cocaine, 857
 Intravenous, 309
 In vitro binding, 41
 In vivo microdialysis in freely moving rats, 99
 Ipsapirone, 825, 891
 Isolation, 41
 Isradipine, 243
 IV, 919
 Juvenile rats, 987
 κ -Agonists, 411
κ-Opioid, 863
κ-Receptor, 665
 K⁺ channel opener, 839
 Lamotrigine, 559
 Lapping, 853
 Lateral hypothalamus, 417
 Laterodorsal tegmental nucleus, 323
 Learning, 317, 385, 765
 Learning/memory, 735, 943
 Licking, 853
 Lithium, 511
 Locomotion, 335, 935
 Locomotor activity, 87, 191, 257, 481, 535, 623
 Long-term facilitation, 735
 Loreclezole, 723
 Loss of control, 11
 Low responder, 191
 Lymphocyte, 227
 LY262691, 493

- Majonoside-R2, 957
 Male, 433
 Maze, 463
 Maze-learning selected chicks, 581
 Mazindol, 911
 MBDB, 99
 mCPP, 107
 MDMA, 99, 455, 477
 Medial frontal cortex, 641
 Medial prefrontal cortex, 5
 Memantine, 791
 Membrane, 27
 Memory, 51, 317, 361, 385
 Memory and learning, 713
 Menthol, 355
 Metergoline, 1023
 Methamphetamine, 575
 Methiothepin, 155
 Methylecgonidine, 57
 Methylhaloxonium, 809
 Mice, 285, 329, 411, 425, 433, 437, 701, 735, 843
 Microdialysis, 221, 575, 679, 747, 809
 Microwaves, 613
 Midazolam, 649
 (-) Eticlopride, 525
 (-)-Norpseudoephedrine, 297
 (-)-3-PPP, 903
 MK-801, 369, 701
 MMAI, 99
 Moclobemide, 469
 Morphine, 227, 411, 433, 511, 531, 731, 791, 809, 979, 1013
 Morphine derivatives, 665
 Morris maze, 163
 Morris water maze, 303, 783
 Motility, 525
 Motivation, 115
 Motor, 179
 Mouse, 673, 877
 Mouse spleen, 141
 MSG, 425
 Mu-opioid, 927
 μ -Receptor, 665
 Muscimol, 629, 971
 Naloxone, 81, 411, 885
 Naltrexone, 987
 Naltrindole, 477
 Neonatal exposure, 197
 Neuroactive steroid, 27
 Neuroactive steroids, 777
 Neurosteroids, 27, 51
 Nicotinamide, 783
 Nicotine, 81, 309, 355
 Nicotine abstinence, 81
 Nicotine dependence, 81
 Nicotine withdrawal, 81, 635
 Nictitating membrane, 617, 857
 Nitric oxide, 147, 673, 1013
 NMDA antagonists, 799
 NMDA receptor antagonists, 701, 791
 NMDA receptors, 799
N-Methyl-DL-aspartate, 673
*N*⁶-*p*-Sulfophenyladenosine (*p*-SPA), 341
 Nociception, 27, 133
 N- ω -Nitro-L-arginine, 673
 Nongenomic, 27
 Nootropic, 943
 Noradrenaline, 285, 541
 Noradrenergic, 979
 Noradrenergic activity, 517
 Nor-binaltorphimine, 411
 Norcocaine, 133
 Norepinephrine, 141, 213, 235, 641, 1023
 Novelty, 191
 NPC 17742, 791
 NS-3 (CG3703), 391
 Nucleus accumbens, 99, 221, 635, 747, 809
 Nucleus basalis, 277
 Nucleus basalis magnocellularis (NBM), 391
 Obesity, 425, 549
 Object recognition, 277
 Obsessive-compulsive disorder, 123
 Ontogeny, 575
 OPC-14597, 903
 Open field, 303
 Open-field test, 833
 Operant response, 335
 Operant test battery, 115
 Opiate antagonists, 81, 987
 Opiates, 11, 81, 809, 871
 Opioids, 67, 433, 871, 885, 987
 Oral, 919, 995
 Oral movements, 935
 Organophosphate, 771
 ORG2766, 163
 Osmotic minipumps, 713
 Pain, 411, 449, 567
 Palatability, 221, 731
 Panax ginseng, 185
 Paradoxical sleep, 291
 Paraventricular nucleus, 1023
 Parental behavior, 987
 Parkinsonian bradykinesia, 335
 Parkinsonism, 179
 Partial agonists, 87
 Particle-size aerosol, 57
 Passive avoidance, 735
 Passive avoidance response, 391
 Pavlovian conditioning, 617
 Peak force, 853
 Peak procedure, 759
 Pedunculopontine tegmental nucleus, 323
 Penile erection, 525
 Pentobarbital-induced sleep, 957
 Pentylenetetrazole, 73, 673
 Performance, 317
 Peripheral chemoreceptors, 341
 Petit mal, 73
 PGO waves, 323
 Phaclofen, 73
 Phenobarbital, 369, 559
 PI turnover, 107
 Picrotoxin, 673
 Piracetam, 943
 Place aversion, 99
 Place conditioning, 487, 511
 Place preference, 511, 1013
 Plaque-forming cell response, 235
 Plasma, 927
 Plasticity, 147
 (+)-Amphetamine, 455
 (+)-Fenfluramine, 455
 (+)MK-801, 799
 (\pm)Cyanopindolol, 257
 Plus-maze, 1005
 Polydrug exposure, 197
 Postictal prolactin, 503
 Prazosin, 979
 Prefrontal cortex, 809
 Pregnenolone, 51, 777
 Pregnenolone sulfate, 51
 Prenatal, 843
 Prenatal alcohol effects, 197
 Prenatal cocaine, 617, 857
 Prenatal cocaine effects, 197
 Prenatal ethanol intoxication, 361
 Prepubertal, 987
 Pressure, 257
 Problem solving, 197
 Progestin, 27
 Progressive ratio, 5, 115
 Prolactin, 379, 641
 Propranolol, 979
 pseudo-Parkinsonism, 853
 Psychological stress, 957
 Psychomotor performance, 265
 Purposeless chewing, 179
 Pyruvate kinase, 549
 Quinpirole, 379, 759
 Rabbit, 857
 (R)- α -methylhistamine, 567
 Race, 355
 Rat pup, 41
 Rats, 1, 11, 73, 205, 249, 271, 291, 335, 341, 379, 385, 391, 433, 455, 463, 531, 559, 593, 657, 679, 765, 809, 853, 871, 891, 919, 971, 979, 1013
 Rearing, 877
 Receptor, 995
 Reference memory, 463
 Reflex modification, 857
 Reinforcement, 5, 243, 657, 971
 Repeated prenatal exposure, 771
 Repeated testing procedures, 369
 Resistance, 965
 Response decrements, 853
 Response sequence, 335
 Restraint, 205, 927
 Retrograde messenger, 147
 Reward, 99, 191, 417, 657, 695, 731
 Ritanserin, 603
 RO 41-9067, 291
 Ro16-6028, 87
 Ro23-1590, 87
 Ro23-0364, 87
 Rotation, 903
 RTI-55, 911
 RU 24969, 535
 Running wheel activity, 329
 Saccharin, 919
 Saccharin taste aversion, 695
 Saclofen, 73
 Salbutamol, 979
 Schizophrenia, 493
 SCH23390, 437, 759
 Scopolamine, 277, 463, 679, 713, 735, 853
 Seizure, 73
 Selected rat lines, 723
 Selective breeding, 871
 Self-administration, 5, 919, 971
 Self-stimulation, 417
 Sensitization, 441, 585, 623, 911, 935
 Sensorimotor, 701
 Sensorimotor integration, 857
 Sensory gating, 817
 Septal area, 541
 Serotonin, 123, 257, 271, 323, 455, 441, 549, 641, 765, 747, 825, 863, 891

- Serotonin agonists, 385
 Serotonergic activity, 517
 Serotonin (5-HT), 425
 Serotonin receptors, 33
 Serotonin reuptake inhibitor, 123
 Serotonin₂ receptors, 603
 7-Hydroxy-*N,N*-di-*n*-propyl-2-aminotetralin, 695
 7-OH-DPAT, 379, 695
 17 β -Estradiol, 379
 Sex, 433
 Sexual behavior, 329, 525
 Sigma receptor, 695
 6-Hydroxydopamine, 5, 817
 SKF 38393, 759
 Sleep, 1
 Sleep apneas, 341
 Sleep-wake cycle, 559
 Smoking, 309
 Social behavior, 11
 Social isolation, 11, 531
 Spatial learning, 303, 361
 Spatial learning and memory, 701
 Spatial working memory, 541
 SRBC, 235
 Stereotyped behavior, 525
 Stereotypy, 903, 935
 Steroid mechanism, 27
 Stimulants, 481
 Stone maze, 713
 Stress, 41, 123, 205, 235, 641, 735
 Stress model, 469
 Stress susceptibility, 581
 Striatum, 179, 257, 575, 635
 Strong learning, 629
 Subdiaphragmatic vagotomy, 839
 Substantia nigra, 493
 Substantia nigra lesions, 503
 Sucrose, 731, 971
 Sweet solution consumption, 243
 Tail-flick latency, 27
 Tail-flick test, 665
 Taste, 731
 Taste aversion, 511, 839
 Taste avoidance, 511
 Taste reactivity, 731
 Temporal response differentiation, 115
 TFMPP
 Thigmotaxia, 303
 Time course, 369, 935
 Time estimation, 115, 759
 Tolerance, 227, 593
 Tongue, 853
 Tongue protrusions, 935
 Topography, 355
 Tremor, 179
 Triazolam, 317
 Trifluperazine, 155
 Trihexyphenidyl, 463
 Tropane, 133
 Turnover, 41
 (2-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide), 33
 Type A monoamine oxidase inhibitor, 469
 U-50488H, 411
 U78875, 87
 Uncontrollable foot-shock, 877
 Undernourished pigeon, 951
 Vacuous chewing, 179
 Vacuous chewing movements, 401
 Valium, 317
 Vapor pressure, 57
 Ventral tegmental area (VTA), 971
 Ventral tegmentum, 493
 Viable yellow, 425
 Vietnamese ginseng extract, 957
 Vietnamese ginseng total saponin, 957
 Vocal control system, 213
 Voltammetry, 257
 Water intake, 297
 Water maze, 317, 385
 Weak learning, 629
 Withdrawal, 249, 593, 791, 809
 Women, 355
 Working memory, 277, 463
 Yawning, 903, 1017
 Yohimbine, 979
 ZG-63, 723
 Zolpidem, 723